DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1004 Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular
risk associated with celecoxib in a clinical trial for colorectal
adenoma prevention. N Engl J Med, 2005, 352:
1071–1080.
Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib
on cardiovascular events and blood pressure in two trials
for the prevention of colorectal adenomas. Circulation,
2006, 114:1028–1035.
Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib,
a cyclooxygenase-2 inhibitor, in familial adenomatous
polyposis. N Engl J Med, 2000, 342:1946–1952.
Terkeltaub R, Bushinsky DA, Becker MA. Recent developments
in our understanding of the renal basis of hyperuricemia and
the development of novel antihyperuricemic therapeutics.
Arthritis Res Ther, 2006, 8(suppl):S4.
Terkeltaub RA. Clinical practice. Gout. N Engl J Med, 2003,
349:1647–1655.
U.S. Food and Drug Administration. COX-2 Selective and Non-
Selective Non-Steroidal Anti-Inflammatory Drugs, updated
03/03/2010. Available at: www.fda.gov/drugs/drugsafety/
postmarketdrugsafetyinformationforpatientsandproviders/ucm
103420.htm, accessed July 30, 2010.
SECTION IV
INFLAMMATION, IMMUNOMODULATION, AND HEMATOPOIESIS
Vane JR, Botting RM. Mechanism of action of nonsteroidal antiinflammatory
drugs. Am J Med, 1998, 104:2S–8S; discussion
21S–22S.
Vanegas H, Schaible HG. Prostaglandins and cyclooxygenases in
the spinal cord. Prog Neurobiol, 2001, 64:327–363.
Veys EM. 20 years’ experience with ketoprofen. Scand J
Rheumatol Suppl, 1991, 90(suppl):1–44.
Villar J, Abalos E, Nardin JM, et al. Strategies to prevent and
treat preeclampsia: Evidence from randomized controlled
trials. Semin Nephrol, 2004, 24:607–615.
Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities
for cyclo-oxygenase-1 rather than cyclo-oxygenase-2
are associated with human gastrointestinal toxicity: A full in
vitro analysis. Proc Natl Acad Sci U S A, 1999, 96: 7563–7568.
Worobec AS. Treatment of systemic mast cell disorders. Hematol
Oncol Clin North Am, 2000, 14:659–687, vii.
Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents
aspirin and salicylate inhibit the activity of I(kappa)B kinasebeta.
Nature, 1998, 396:77–80.
Yu Y, Cheng Y, Fan J, et al. Differential impact of prostaglandin
H synthase 1 knockdown on platelets and parturition. J Clin
Invest, 2005, 115:986–995.